2019 PharmSci 360
N-glycosylation is an important post-translational modification and often results in glycan heterogeneity. Understanding the relationship between glycoform characteristics and PK/PD properties can inform the need for controlling glycosylation during product development. Most therapeutic mAbs contain a glycosylation site (Asn 297) in the Fc region. Mannose, sialic acids, fucose, and galactose are among glycans with reported impact. Mannose receptors function by binding to both high-mannose-containing pathogens and endogenous proteins to clear them from circulation; thus, mAb glycoforms that contain high-mannose structures may have faster clearance due to binding to mannose receptors. This presentation will provide information as to how glycosylation can influence PK of therapeutic proteins.